Qiagen N.V.

NYSE:QGEN

Medical - Diagnostics & Research

Healthcare
$49.56 -0.96%

-$0.35 today

Market cap
$10.23B
Beta
0.66
P/E (TTM)
18.6
EPS (TTM)
$1.94
Dividend yield
0.69%
52W Low $32.53High $57.82

Volume 4.26M

Average 2.07M

QGEN Pre-Tax Margin

Income before tax as a percentage of revenue.

Qiagen N.V.NYSE: QGEN

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin widens to 24.7%

Pre-tax margin was 24.7% in Q2 FY2026, up 0.9 pp from a year earlier. On a trailing-twelve-month basis it was 22.0%, down 2.0 pp year over year. Over 3 fiscal years it narrowed by 0.5 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
24.7%+7.3 pp QoQ
Last fiscal yearDec 2025
23.5%+17.3 pp YoY
LTMJun 2026
22.0%-2.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.9 pp——
1 year+17.3 pp——
3 years-0.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.5%
Year-over-year change
+17.3pp

Pre-Tax Margin vs competitors

How QGEN compares with its peers on the latest reported figures

  • QGEN's LTM Jun 2026 pre-tax margin of 22.0% is the 2nd highest of the 11 companies compared; the peer median is 11.2%.
  • Its year-over-year change of -2.0 pp is the 8th highest of 11, against a peer median of +1.2 pp.
  • Over three fiscal years its change of -0.5 pp compares with a peer median of -9.8 pp.
QGEN Competitors Peer median
Pre-Tax Margin for QGEN and competitors
Company Period LTM level YoY 3-year change
AAgilent Technologies, Inc.LTM Jul 202622.5% +2.0 pp-1.3 pp
QGENQiagen N.V.LTM Jun 202622.0% -2.0 pp-0.5 pp
DHRDanaher CorporationLTM Sep 202618.8% +1.6 pp-9.6 pp
TECHBio-Techne CorporationLTM Sep 202618.5% +9.8 pp-10.0 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202616.6% +0.3 pp-0.8 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202613.5% -4.1 pp+206.4 pp
RVTYRevvity, Inc.LTM Jul 20269.0% -2.3 pp-10.3 pp
RGENRepligen CorporationLTM Jun 20266.6% +8.7 pp-18.9 pp
BRKRBruker CorporationLTM Jun 2026-0.8% -4.8 pp-15.8 pp
TXG10x Genomics, Inc.LTM Sep 2026-10.5% +0.9 pp+25.2 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-65.4% +96.3 pp-189.0 pp
Peer median (excluding QGEN) 11.2%+1.2 pp-9.8 pp

Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.25B2.14B1.97B1.98B2.09B
Cost of Revenue800.84M756.96M731.62M1.01B798.5M
Gross Profit1.45B1.38B1.23B967.35M1.29B
Gross Margin64.4%64.7%62.8%48.9%61.8%
Research & Development189.96M189.86M198.51M193.49M187.52M
Selling, General & Admin584.47M603.95M579.17M564.36M583.67M
Operating Expenses820.74M853.1M823.75M869.64M771.19M
Depreciation & Amortization214.93M208.4M205.34M203.27M193.75M
EBITDA895.24M779.36M688.56M368.26M717.27M
EBITDA Margin39.8%36.4%35.0%18.6%34.3%
Operating Income630.08M531.46M409.94M97.71M520.31M
Operating Margin28.0%24.8%20.9%4.9%24.9%
Interest Income9.56M32.76M78.99M68.02M64.32M
Interest Expense54.48M58.36M53.41M43.84M33.26M
Other Income / Expenses(4.25M)(18.86M)19.87M23.44M(30.04M)
Income Before Tax625.83M512.6M429.81M121.15M490.27M
Pre-Tax Margin27.8%23.9%21.9%6.1%23.5%
Income Tax Expense113.23M89.39M88.51M37.56M65.39M
Net Income512.6M423.21M341.3M83.59M424.88M
Net Margin22.8%19.8%17.4%4.2%20.3%
EPS (Basic)2.522.081.670.392.04
EPS (Diluted)2.472.051.650.382.04
Weighted Avg Shares221.14M220.75M217.49M216.44M207.94M
Weighted Avg Shares (Diluted)225.07M223.23M217.49M218.48M207.94M

Qiagen N.V.

NYSE:QGEN

Intrinsic Alpha fair value

Locked

Current Price

$49.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.